351 results on '"Dougall, William C."'
Search Results
2. Author Correction: The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation
3. Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma
4. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells
5. The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation
6. RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer
7. RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer
8. NMDAR antagonists suppress tumor progression by regulating tumor-associated macrophages
9. Retraction: CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms
10. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms
11. Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
12. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)
13. RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer.
14. Supplementary Data from CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
15. Supplementary Methods and Legends from CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
16. Data from CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
17. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
18. RANK and RANK ligand expression in primary human osteosarcoma
19. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression
20. New Targeted Therapies for Bone Metastases
21. Supplementary Methods and References from RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation
22. Supplementary Figure 1 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
23. Supplementary Figure S3 from RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation
24. Supplementary Table S1 from RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation
25. Supplementary Figure 7 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
26. Data from RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation
27. Supplementary Figure 5 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
28. Supplementary Methods, Figure Legends 1-7 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
29. Data from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
30. Supplementary Figure 3 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
31. Supplementary Figure 4 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
32. Supplementary Figure 2 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
33. Supplementary Table and Figure Legends from RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation
34. Supplementary Figure 6 from RANK Induces Epithelial–Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis
35. RANK Ligand Is a Therapeutic Target in Multiple Myeloma
36. RANKL Inhibition Blocks Osteolytic Lesions and Reduces Skeletal Tumor Burden in Models of Non–Small-Cell Lung Cancer Bone Metastases
37. RANKL Inhibition: From Mice to Men (and Women)
38. NMDAR antagonists suppress tumor progression by regulating tumor-associated macrophages.
39. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers
40. Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma
41. Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma
42. Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical Method
43. Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion
44. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
45. RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase
46. RANK expression as a prognostic and predictive marker in breast cancer
47. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis
48. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms
49. RANK expression on breast cancer cells promotes skeletal metastasis
50. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.